PMID- 12085971
OWN - NLM
STAT- MEDLINE
DCOM- 20021220
LR  - 20191106
IS  - 0167-7659 (Print)
IS  - 0167-7659 (Linking)
VI  - 20
IP  - 3-4
DP  - 2001
TI  - Signal transduction targets in androgen-independent prostate cancer.
PG  - 351-62
AB  - Prostate cancer (PCa) first manifests as an androgen-dependent disease. Thus, 
      androgen-deprivation therapy is a standard regimen for patients with metastatic 
      PCa. Despite the initial success of androgen-deprivation therapy, PCa inevitably 
      progresses from being androgen dependent (AD) to androgen independent (AI), and 
      this marks the poor prognosis of this disease. Relapse of AIPCa becomes life 
      threatening and accounts for the majority of mortality of PCa patients. 
      Currently, no effective therapy is available for controlling AIPCa. Therefore, 
      the challenge in providing a new intervention is to understand the fundamental 
      changes that occur in AIPCa. Increasing evidence indicates that, under 
      androgen-deprived milieu, several signal networks elicited by peptide growth 
      factors dictate the AI phenotype of PCa. This review covers the latest studies 
      investigating the potential involvement of autocrine growth factors in cell 
      proliferation, survival, metastasis, and the reciprocal interaction with the 
      androgen receptor pathway. In addition, loss of the negative feedback mechanism 
      of the signal cascade further amplifies the effect of growth factors, and thus 
      contributes significantly to the onset of AIPCa. The understanding of the signal 
      target(s) in AIPCa should provide the new markers for prognosis and a new 
      strategy for prevention and therapy.
FAU - Zhou, J
AU  - Zhou J
AD  - Department of Urology, University of Texas Southwestern Medical Center at Dallas, 
      75390-9110, USA.
FAU - Scholes, J
AU  - Scholes J
FAU - Hsieh, J T
AU  - Hsieh JT
LA  - eng
GR  - DK 4765707/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - Netherlands
TA  - Cancer Metastasis Rev
JT  - Cancer metastasis reviews
JID - 8605731
RN  - 0 (Androgens)
RN  - 0 (Receptors, Androgen)
SB  - IM
MH  - Adenocarcinoma/*metabolism/pathology/therapy
MH  - Androgens/*therapeutic use
MH  - Cell Division
MH  - Disease Progression
MH  - Humans
MH  - Male
MH  - Neoplasms, Hormone-Dependent/*metabolism/pathology/therapy
MH  - Prostatic Neoplasms/*metabolism/pathology/therapy
MH  - Receptors, Androgen/metabolism
MH  - Signal Transduction/*physiology
RF  - 122
EDAT- 2002/06/28 10:00
MHDA- 2002/12/21 04:00
CRDT- 2002/06/28 10:00
PHST- 2002/06/28 10:00 [pubmed]
PHST- 2002/12/21 04:00 [medline]
PHST- 2002/06/28 10:00 [entrez]
AID - 10.1023/a:1015504015302 [doi]
PST - ppublish
SO  - Cancer Metastasis Rev. 2001;20(3-4):351-62. doi: 10.1023/a:1015504015302.